| 000 | 01783 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514021601.0 | ||
| 264 | 0 | _c20020617 | |
| 008 | 200206s 0 0 eng d | ||
| 022 | _a0065-2598 | ||
| 024 | 7 |
_a10.1007/978-1-4615-0685-0_60 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNawrocki, S | |
| 245 | 0 | 0 |
_aHumoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor. _h[electronic resource] |
| 260 |
_bAdvances in experimental medicine and biology _c2001 |
||
| 300 |
_a411-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Neoplasm _xbiosynthesis |
| 650 | 0 | 4 |
_aAntigens, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aAutoantigens _xgenetics |
| 650 | 0 | 4 |
_aCancer Vaccines _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-6 _xgenetics |
| 650 | 0 | 4 |
_aIsoantigens _xgenetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xgenetics |
| 650 | 0 | 4 | _aMelanoma-Specific Antigens |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMonophenol Monooxygenase _xgenetics |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xgenetics |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aReceptors, Interleukin-6 _xbiosynthesis |
| 650 | 0 | 4 | _aSolubility |
| 700 | 1 | _aĹaciak, M | |
| 700 | 1 | _aIzycki, D | |
| 700 | 1 | _aGryska, K | |
| 700 | 1 | _aWysocki, P J | |
| 700 | 1 | _aGrabarczyk, P | |
| 700 | 1 | _aKarczewska, A | |
| 700 | 1 | _aKaczmarek, A | |
| 700 | 1 | _aMurawa, P | |
| 700 | 1 | _aMalicki, J | |
| 700 | 1 | _aRose-John, S | |
| 700 | 1 | _aMackiewicz, A | |
| 773 | 0 |
_tAdvances in experimental medicine and biology _gvol. 495 _gp. 411-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/978-1-4615-0685-0_60 _zAvailable from publisher's website |
| 999 |
_c11686480 _d11686480 |
||